CMPX
Compass Therapeutics Inc.
$4.31
+$0.06(+1.53%)
64
Overall
60
Value
91
Tech
42
Quality
Market Cap
$468.78M
Volume
1.41M
52W Range
$1.27 - $4.31
Target Price
$12.91
Order:
Income Statement
| Metric | Trend | Chart | 2019 Mar | 2020 Mar | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | -- | -- | -- | -- | $850.0K | ||
| Total Revenue | -- | -- | -- | -- | -- | -- | $850.0K | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | -- | -- | -- | -- | $850.0K | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $32.8K | $32.1K | $27.8M | $81.9M | $41.7M | $50.4M | $57.5M | ||
| Research & Development | -- | -- | $14.9M | $71.0M | $30.0M | $38.1M | $42.3M | ||
| Research Expense | -- | -- | $14.9M | $71.0M | $30.0M | $38.1M | $42.3M | ||
| Selling, General & Administrative | $32.8K | $32.1K | $12.9M | $10.9M | $11.7M | $12.2M | $15.1M | ||
| General & Administrative Expenses | $32.8K | $32.1K | $12.9M | $10.9M | $11.7M | $12.2M | $15.1M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | $6.1M | $8.6M | ||
| Depreciation & Amortization | -- | -- | $2.4M | $600.0K | $800.0K | $700.0K | $600.0K | ||
| Depreciation & Amortization | -- | -- | $2.4M | $600.0K | $800.0K | $700.0K | $600.0K | ||
| OPERATING INCOME | |||||||||
| Operating income | $-32.8K | $-32.1K | $-27.8M | $-81.9M | $-41.7M | $-50.4M | $-56.6M | ||
| EBITDA | $-32.8K | $-32.1K | $-26.2M | $-80.2M | $-39.8M | $-43.8M | $-49.3M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $3.3K | $5.4K | $908.0K | $370.0K | -- | -- | -- | ||
| Intinc | -- | -- | $88.0K | $29.0K | $2.4M | $7.9M | $7.3M | ||
| Net Non-Operating Interest Income/Expense | $-3.3K | $-5.4K | $-820.0K | $-341.0K | $2.4M | $7.9M | $7.3M | ||
| Other Income/Expense | -- | -- | $1.7M | $299.0K | $70.0K | $-7.9M | $-7.3M | ||
| Other Special Charges | -- | -- | $-1.7M | $-299.0K | $2.4M | $7.9M | $7.3M | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-32.8K | $-32.1K | $-28.6M | $-81.8M | $-41.7M | $-42.5M | $-49.4M | ||
| Pre-Tax Income | $-36.0K | $-37.5K | $-29.5M | $-82.2M | $-39.2M | $-42.5M | $-49.4M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-7.6K | $-7.9K | $32.0K | -- | -- | -- | -- | ||
| NET INCOME | |||||||||
| Net Income | $-36.0K | $-37.5K | $-29.5M | $-82.2M | $-39.2M | $-42.5M | $-49.4M | ||
| Net Income (Continuing Operations) | $-36.0K | $-37.5K | $-29.5M | $-82.2M | $-39.2M | $-42.5M | $-49.4M | ||
| Net Income (Discontinued Operations) | $-36.0K | $-37.5K | $-29.5M | $-82.2M | $-39.2M | $-42.5M | $-49.4M | ||
| Net Income (Common Stockholders) | $-36.0K | $-37.5K | $-29.5M | $-82.2M | $-39.2M | $-42.5M | $-49.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-48.9M | ||
| TOTALS | |||||||||
| Total Expenses | $32.8K | $32.1K | $27.8M | $81.9M | $41.7M | $50.4M | $57.5M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $5.0M | $5.0M | $30.8M | $62.9M | $105.2M | $127.0M | $137.4M | ||
| Average Shares Outstanding (Diluted) | $5.0M | $5.0M | $30.8M | $62.9M | $105.2M | $127.0M | $137.4M | ||
| Shares Outstanding | $138.3M | $138.3M | $52.1M | $101.3M | $126.5M | $138.3M | $138.3M | ||
| Basic EPS | $-0.01 | $-0.01 | $-0.96 | $-1.31 | $-0.37 | $-0.33 | $-0.36 | ||
| Basic EPS (Continuing Operations) | $-0.01 | $-0.01 | $-0.96 | $-1.31 | $-0.37 | $-0.33 | $-0.36 | ||
| Diluted EPS | $-0.01 | $-0.01 | $-0.96 | $-1.31 | $-0.37 | $-0.33 | $-0.36 | ||
| OTHER METRICS | |||||||||
| Gain On Sale Of P P E | -- | -- | $-281.0K | $42.0K | -- | -- | -- | ||
| Other Gand A | $32.8K | $32.1K | $12.9M | $10.9M | $11.7M | $12.2M | $15.1M | ||
| Rent And Landing Fees | -- | -- | $2.0M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CMPX | $4.31 | +1.5% | 1.41M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Compass Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW